Litigation Details for BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. v. HETERO USA INC. (D.N.J. 2017)

BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. v. HETERO USA INC. (D.N.J. 2017)

Docket	3:17-cv-07923	Date Filed	2017-10-05
Court	District Court, D. New Jersey	Date Terminated	2018-05-02
Cause	15:1126 Patent Infringement	Assigned To	Michael Andre Shipp
Jury Demand	None	Referred To	Lois H. Goodman
Patents	8,426,586; RE43,431
Link to Docket	External link to docket

Details for BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. v. HETERO USA INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-10-05				External link to document
2017-10-05	1		United States Patent No. 8,426,586. A true and correct copy of United States Patent No. 8,426,586 is attached… infringement of United States Patent No. 8,426,586 (“the ’586 Patent”). This Court has jurisdiction … US 8,426,586 B2 Page 2 FOREIGN PATENT DOCUMENTS…PageID: 16 US. Patent Apr. 23, 2013 Sheet 1 of2 US 8,426,586 B2 … US 8,426,586 B2 Soyka et a].	External link to document

Boehringer Ingelheim v. Hetero USA: Spiriva Respimat Patent Litigation Summary

Last updated: September 2, 2026

Boehringer Ingelheim Pharmaceuticals sued Hetero USA and related Hetero entities in the District of New Jersey under the Hatch-Waxman Act after Hetero filed an ANDA seeking approval for a generic version of Spiriva Respimat, a tiotropium bromide inhalation spray. The case, No. 3:17-cv-07923, was an ANDA litigation proceeding rather than a product-liability or antitrust action. The dispute centered on patents covering tiotropium formulations and the Respimat delivery system. The case ended without a publicly reported merits judgment invalidating the asserted patents.

What drug was at issue in Boehringer Ingelheim v. Hetero USA?

The litigation concerned Spiriva Respimat, whose active ingredient is tiotropium bromide. Spiriva Respimat is a prescription inhaled anticholinergic bronchodilator used for maintenance treatment of chronic obstructive pulmonary disease.

Item	Detail
Brand	Spiriva Respimat
Active ingredient	Tiotropium bromide
Dosage form	Metered inhalation spray
Device	Respimat inhaler
NDA holder	Boehringer Ingelheim Pharmaceuticals, Inc.
Regulatory pathway	ANDA litigation under 21 U.S.C. § 355(j)
Defendant	Hetero USA Inc. and affiliated Hetero entities
Court	U.S. District Court for the District of New Jersey
Civil action	3:17-cv-07923
Case type	Hatch-Waxman patent infringement

Spiriva Respimat is distinct from Spiriva HandiHaler. The HandiHaler product uses tiotropium powder capsules, while Respimat uses a liquid formulation delivered through a soft-mist inhaler. That distinction affects both the asserted patent scope and the technical design-around options available to a generic manufacturer.

What patents protected Spiriva Respimat in the Hetero litigation?

The asserted estate included patents directed to tiotropium pharmaceutical formulations and inhalation delivery technology. Public patent and Orange Book records identify several Boehringer patents associated with Spiriva products, including the following patent families.

Patent	General subject matter	Relevance
U.S. Patent No. 8,337,921	Tiotropium-containing pharmaceutical formulation	Formulation protection
U.S. Patent No. 8,865,688	Inhalation formulation and delivery technology	Formulation and device-related protection
U.S. Patent No. 9,205,123	Tiotropium inhalation formulation technology	Later-generation formulation protection

Patent scope and assertion can differ by defendant and ANDA. A patent listed in the Orange Book is not necessarily asserted in every litigation. The operative complaint, amended pleadings, and infringement contentions control the patents actually placed in dispute.

The litigation’s commercial value derived from the combination of formulation and device claims. A generic manufacturer could potentially avoid a single formulation patent by modifying excipients or concentration, but avoiding a patent estate covering both the liquid formulation and the inhalation device is more difficult.

What triggered the Boehringer v. Hetero lawsuit?

Hetero submitted an ANDA with a Paragraph IV certification challenging one or more patents listed for Spiriva Respimat. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.

Boehringer responded by filing suit under 35 U.S.C. § 271(e)(2). The filing of an ANDA is treated as an artificial act of infringement for purposes of resolving the patent dispute before generic approval and commercial launch.

The lawsuit triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to possible termination or modification by court order. The stay protected Boehringer from an immediate FDA approval while the patent claims were litigated or otherwise resolved.

Was Hetero’s product a generic or a biosimilar?

Hetero’s proposed product was a small-molecule generic, not a biosimilar.

The relevant pathway was an ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The case did not involve:

• A biologic license application;
• A biosimilar application under Section 351(k) of the Public Health Service Act;
• Interchangeability standards;
• Biologic patent-exchange procedures under the Biologics Price Competition and Innovation Act.

Biosimilar risk is therefore not applicable to this docket. The commercial risk was generic substitution through an ANDA approved by FDA.

What was the litigation timeline?

The principal procedural timeline was as follows:

Date or period	Event
2017	Hetero filed an ANDA containing Paragraph IV patent certifications for the proposed tiotropium product.
October 2017	Boehringer commenced Civil Action No. 3:17-cv-07923 in the District of New Jersey.
2018-2019	The parties litigated patent infringement, validity, claim construction, and related Hatch-Waxman issues.
Subsequent period	The case was resolved and terminated without a reported public trial judgment declaring the principal Spiriva Respimat patent estate invalid.

The docket did not produce a widely cited Federal Circuit merits decision. That materially limits the precedential value of the case. Its primary significance was commercial: it delayed or conditioned Hetero’s ability to obtain FDA approval and launch.

What was the Paragraph IV challenge?

Hetero’s Paragraph IV position placed patent validity and infringement at issue before the proposed product could reach the market. The principal legal questions in this type of case were:

1. Whether Hetero’s ANDA product would infringe the asserted formulation or device claims;
2. Whether the asserted patents were invalid for anticipation or obviousness;
3. Whether the patents were enforceable;
4. Whether the claims covered the specific concentration, excipient profile, delivery characteristics, and device configuration disclosed in Hetero’s ANDA.

For an inhalation product, infringement analysis is highly dependent on the ANDA’s precise formulation and device specifications. The analysis may involve active-ingredient concentration, preservative or excipient content, particle or droplet characteristics, container configuration, actuator operation, and dose-delivery performance.

What was the Orange Book status of Spiriva Respimat?

Spiriva Respimat was subject to FDA Orange Book patent listings for patents covering the drug product and its delivery technology. Orange Book listing creates the basis for Paragraph IV certification and Hatch-Waxman litigation.

Orange Book status should be separated into three categories:

Issue	Effect
Patent listing	Identifies patents submitted by the NDA holder for the listed drug
Paragraph IV certification	Allows the ANDA applicant to challenge listed patents
30-month stay	Delays FDA approval after a timely patent-infringement suit

Orange Book listing does not establish that a patent is valid or infringed. A listed patent can later be narrowed, invalidated, delisted, or rendered commercially irrelevant by a design-around.

When does Spiriva Respimat lose exclusivity?

Spiriva Respimat exclusivity is determined by the combined effect of FDA regulatory exclusivity, patent expiration, pediatric extensions, litigation settlements, and any authorized-generic arrangements.

The principal commercial limitation was patent protection rather than traditional FDA new-chemical-entity exclusivity. Tiotropium itself had been marketed for years before the Hetero case. The relevant later-expiring protection related to Respimat formulations and delivery technology.

Patent-term estimates associated with the Spiriva Respimat estate extended into the mid-to-late 2020s, depending on the specific patent, patent-term adjustment, and any pediatric extension. The earliest expiration date does not necessarily establish the first lawful generic launch date because later patents, settlement restrictions, and FDA approval timing can control market entry.

What formulations were protected?

The patent estate protected more than the tiotropium molecule. The relevant protection included product attributes such as:

• A liquid tiotropium formulation suitable for soft-mist delivery;
• Concentration and dose characteristics;
• Excipients and stabilizing components;
• Formulation performance during storage;
• Metered-dose delivery through the Respimat platform;
• Components of the inhaler and related delivery configuration.

Formulation patents are commercially important in inhaled products because a generic may have difficulty demonstrating pharmaceutical equivalence while materially changing the formulation or device. The ANDA applicant must satisfy FDA requirements for sameness or permitted differences, while also avoiding the branded manufacturer’s patent claims.

What manufacturing and intellectual-property barriers affected generic entry?

The principal barriers were technical replication, device qualification, regulatory equivalence, and patent clearance.

Formulation development

A generic developer must produce a stable liquid formulation with reproducible tiotropium concentration and dose delivery. Changes in excipients can affect chemical stability, delivered dose, spray characteristics, and shelf life.

Device engineering

Respimat products require a specialized inhaler platform. Device performance can affect plume geometry, droplet size, emitted dose, and patient-use characteristics. A generic device must satisfy FDA requirements while avoiding device or delivery claims.

Manufacturing controls

Inhalation products require controls over filling, container closure, actuator performance, dose uniformity, microbiological quality, and assembly. These requirements increase development costs and reduce the number of capable generic manufacturers.

Patent clearance

A formulation or device change that avoids one patent can create regulatory or performance problems. This raises the cost of a design-around and can extend the time between ANDA filing and commercial launch.

Did Boehringer and Hetero reach a settlement?

The case was resolved without a publicly reported merits decision invalidating the asserted Spiriva Respimat patents. The publicly available case record does not provide a judicial finding that Hetero’s proposed product was noninfringing or that the asserted patents were invalid.

Hatch-Waxman settlements often include confidential commercial terms. Publicly available information may disclose dismissal or termination while withholding:

• The agreed generic launch date;
• Whether Hetero received a license;
• Whether the agreement included an authorized-generic commitment;
• Supply or co-marketing provisions;
• Restrictions on future product modifications.

The absence of a reported invalidity decision means the case did not materially weaken the broader Boehringer patent estate through precedent.

What was the litigation status?

The action was terminated after resolution between the parties. There was no widely reported Federal Circuit opinion establishing a binding rule on the validity or scope of the Spiriva Respimat patents in this specific Hetero case.

The practical result was:

• No public merits judgment against Boehringer;
• No reported final invalidity ruling against the asserted patents;
• No public finding that Hetero could launch immediately;
• Continued relevance of the underlying Orange Book patents to other generic challengers;
• Confidentiality regarding the commercial terms of resolution.

Which companies challenged Spiriva patents?

Boehringer faced multiple generic challenges to Spiriva-related products over time. Potential challengers included manufacturers pursuing tiotropium HandiHaler or Respimat products, but the products were not interchangeable from a patent or regulatory perspective.

The competitive landscape included:

Competitor category	Product issue
Generic inhaler manufacturers	Development of tiotropium equivalents
Device-capable generic companies	Respimat-like soft-mist delivery
Authorized-generic providers	Launch under a Boehringer-linked arrangement
Alternative bronchodilator manufacturers	Competing LAMA or LAMA/LABA therapies
Combination-product companies	Products competing for COPD maintenance prescriptions

The most relevant competitors were companies with inhalation-device manufacturing capability, not simply the largest tablet generic manufacturers.

How strong was the Boehringer patent estate?

The estate was commercially strong but technically specialized.

Strengths

• Protection extended beyond the active ingredient to formulation and delivery;
• Respimat device replication required specialized engineering;
• The product had significant regulatory and manufacturing complexity;
• A Paragraph IV challenge could delay approval through the 30-month stay;
• No public merits judgment in the Hetero case materially undermined the asserted estate.

Weaknesses

• Older tiotropium compound protection had limited remaining value by 2017;
• Formulation claims may be vulnerable to obviousness challenges;
• Generic developers can pursue device or formulation design-arounds;
• Multiple patent expirations create staged entry opportunities;
• Settlement terms can permit delayed generic entry before the last asserted patent expires.

The estate’s strongest value was its ability to delay and increase the cost of generic entry. Its long-term durability depended on the validity of later formulation and device claims, not on the original tiotropium molecule patents.

What generic launch risks existed after the case?

The principal launch scenarios were:

Scenario	Commercial consequence
Full patent win for Boehringer	Hetero approval and launch delayed until patent expiration or license
Hetero validity win	Potential early FDA approval and launch, subject to other patents
Noninfringement finding	Hetero could pursue approval without infringing the adjudicated claims
Confidential settlement	Launch date governed by negotiated terms
Authorized-generic arrangement	Competition could begin before independent generic entry
Device redesign	Hetero could pursue a later approval strategy after patent clearance

The largest exposure was the loss of Spiriva Respimat pricing and volume after the first credible generic or authorized-generic launch. Inhaled products often experience slower substitution than conventional solid oral dosage forms because device familiarity, prescribing habits, payer controls, and patient technique affect conversion rates.

How did Spiriva Respimat compare with other Boehringer products?

Product	Active ingredient	Generic risk profile	Key IP issue
Spiriva Respimat	Tiotropium bromide	High technical barrier	Liquid formulation and soft-mist device
Spiriva HandiHaler	Tiotropium bromide	Device and capsule substitution issues	Dry-powder formulation and inhaler
Jardiance	Empagliflozin	Conventional oral generic pathway	Compound and solid-form patents
Tradjenta	Linagliptin	Conventional oral generic pathway	Compound, formulation, and method-of-use claims
Pradaxa	Dabigatran etexilate	Oral small-molecule generic pathway	Compound, salt, formulation, and use patents

Spiriva Respimat presented a higher manufacturing and device barrier than an oral small-molecule product. That reduced the number of credible generic entrants but did not eliminate Paragraph IV risk.

Key Takeaways

• Boehringer Ingelheim v. Hetero USA, No. 3:17-cv-07923, was a Hatch-Waxman case involving a proposed generic version of Spiriva Respimat.
• The product contained tiotropium bromide and used Boehringer’s Respimat soft-mist inhaler platform.
• The dispute involved formulation and inhalation-delivery patents rather than only the tiotropium active ingredient.
• Hetero’s Paragraph IV certification triggered patent litigation and the statutory FDA approval stay.
• The case ended without a publicly reported merits judgment invalidating the asserted Boehringer patents.
• Settlement terms and any agreed launch date were not publicly disclosed in full.
• Generic-entry risk remained dependent on later-expiring formulation patents, device patents, FDA approval, and potential authorized-generic activity.
• Biosimilar risk was not relevant because the product was a small-molecule drug regulated through the ANDA pathway.

FAQs

What was the case number for Boehringer Ingelheim’s Spiriva Respimat lawsuit against Hetero?

The case was Civil Action No. 3:17-cv-07923 in the U.S. District Court for the District of New Jersey.

Did Hetero receive FDA approval for generic Spiriva Respimat?

The litigation docket does not establish immediate FDA approval or an immediate commercial launch. Approval and launch depended on the ANDA’s regulatory status, patent resolution, and any confidential settlement restrictions.

Did the Hetero case invalidate Boehringer’s Spiriva patents?

No publicly reported merits decision from this case invalidated the principal Spiriva Respimat patents.

Are Spiriva Respimat and Spiriva HandiHaler covered by the same patents?

No. The products use different dosage forms and delivery systems. Respimat uses a liquid soft-mist inhaler, while HandiHaler uses tiotropium powder capsules. Their patent estates overlap in some technical areas but are not identical.

Could a generic manufacturer avoid the Respimat patents with a different inhaler?

Potentially, but a different inhaler would still need to satisfy FDA requirements for pharmaceutical equivalence, dose delivery, usability, device performance, and labeling. A design-around could reduce patent risk while increasing regulatory and manufacturing risk.

References

1. Boehringer Ingelheim Pharmaceuticals, Inc. v. Hetero USA Inc., No. 3:17-cv-07923, U.S. District Court for the District of New Jersey, docket record.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2024). Spiriva Respimat prescribing information. FDA.

4. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Assignment Search records for U.S. Patent Nos. 8,337,921, 8,865,688, and 9,205,123. USPTO.

5. United States Code. (2024). 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).